ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Artiva launches for natural killer cell therapy

by Michael McCoy
July 4, 2020 | APPEARED IN VOLUME 98, ISSUE 26

 

Artiva Biotherapeutics has launched with $78 million in series A funding. The San Diego–based firm says it will use the funds to develop off-the-shelf natural killer cell therapies to be used with monoclonal antibodies and other tumor-targeting therapies. The company will leverage cell-manufacturing technology licensed from GC LabCell, a South Korean firm that provided seed funding to Artiva and is one of its investors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment